Search

Search Results

• 

  PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti^1|2, T. Zollner^1|2, OC. Cretu^1|2, A. Chistolini³, R. Pancani⁴, L. Puccetti⁵, P. Sivera⁶, W. Ageno⁷, G. Elmi⁸, V. Fregoni⁹, V. Tonelli¹⁰, E. Antonucci¹¹, D. Poli^11|12, A. Falanga^1|2, L. Barcella^1|2 | ¹Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; ²ERN EuroBloodNet; ³Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; ⁴Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; ⁵Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; ⁶Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; ⁷Department of Medicine, University of Padua, Padua, Italy; ⁸Department of Medicine, Maggiore Hospital, Bologna, Italy; ⁹Department of Medicine, Sondalo Hospital, Sondalo, Italy; ¹⁰Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; ¹¹Arianna Anticoagulazione Foundation, Bologna, Italy; ¹²Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.520

  114

  PDF: 29
• 

  PO23 | IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA RELATED TO DELAYED IMMUNE CHECKPOINT INHIBITORS TOXICITY: A CASE REPORT E. Galimberti¹, F. Schieppati¹, C. Ambaglio¹, M. Marchetti¹, L. Barcella¹, A. Falanga^1|2 | ¹Immunohematology and Transfusion Medicine Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.518

  102

  PDF: 25
• 

  PO17 | PREDICTIVE VALUE OF INFLAMMATORY AND ENDOTHELIAL BIOMARKERS FOR CANCER RISK IN HEALTHY INDIVIDUALS: EVIDENCE FROM THE HYPERCAN STUDY C. Ticozzi¹, S. Bolognini^1|2, P. Gomez-Rosas^1|3, F. Schieppati^1|2, G. Sampietro⁴, L. Barcella¹, M. Marchetti^1|2, A. Falanga^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; ⁴Unit of Epidemiology and Statistics, ATS Bergamo, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.512

  96

  PDF: 32
• 

  PO60 | VEXAS SYNDROME AS A NEW SEVERE THROMBOPHILIC CLONAL CONDITION: A SINGLE CENTRE EXPERIENCE C. Ambaglio¹, E. Galimberti¹, F. Schieppati¹, M. Frigeni², M. Marchetti¹, L. Barcella¹, A. Falanga ^1|3 | ¹Immunohematology and Transfusion Medicine Unit, ASST Papa Giovanni XXIII, Bergamo; ²Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo; ³School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.551

  127

  PDF: 28
• 

  PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti^1|2|3, P. Gomez-Rosas^1|4|5, S. Bolognini¹, C. Ticozzi¹, D. Romeo¹, F. Schieppati^1|3, L. Barcella^1|3, F. Petrelli⁶, A. D'Alessio⁷, R. Labianca⁷, A. Falanga^1|2|3 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; ³ERN EuroBloodNet; ⁴Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; ⁵Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; ⁶Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; ⁷Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.538

  94

  PDF: 22
• 

  PO43 | ELEVATED CIRCULATING TISSUE PLASMINOGEN ACTIVATOR LEVELS PREDICT GASTROINTESTINAL AND BREAST CANCER RISK: A PROSPECTIVE NESTED CASE-COHORT STUDY S. Bolognini^1|2, C. Ticozzi¹, P. Gomez-Rosas^1|3, F. Schieppati^1|2, G. Sampietro⁴, L. Barcella¹, M. Marchetti^1|2, A. Falanga^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; ⁴Unit of Epidemiology and Statistics, ATS Bergamo, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.537

  118

  PDF: 33
• 

  PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati^1|2, P. Gomez-Rosas^1|3, C. Ambaglio¹, V. Brusegan¹, O.C. Cretu¹, E. Galimberti¹, F. Zunino¹, L. Barcella¹, J. Harenberg^4|5, A. Falanga^1|2, M. Marchetti^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ⁴Ruprecht Karls University of Heidelberg, Heidelberg, Germany; ⁵DOASENSE GmbH, Heidelberg, Germany

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.522

  97

  PDF: 32